17 - 18 November 2021 | Virtual
Vaccine World Asia Congress
Singapore
Join Vaccine World Asia Congress 2021!
800+
High Profile Attendees
200+
Key Stakeholder Companies
50+
Expert Speakers
20+
Hours of Networking
The Concept
Due to increasing healthcare expenditure, advancing vaccine technology, and rising demand for preventives vaccines, especially new COVID-19 vaccines, the Asia-Pacific preventive vaccines market will rise by 12.89% annually with a total addressable market cap of $97.2 billion between 2020 and 2026.
Coronavirus infection has recently infected millions of people all over the world. In certain areas, community transmission has resulted in an increase in global casualties. At present, Big pharma and biopharma are concentrating their efforts on COVID-19 vaccine research and development. The COVID-19 pandemic situation has generated unprecedented demand, and companies are heavily investing in R&D activities, with government support as well as technological advancement to shorten the clinical trial duration and increase production efficiency. The market's growth prospects will be bolstered by the expansion of vaccine manufacturing facilities to meet the rising demand.
Vaccine World Asia Congress 2021 will be the only vaccine-focused platform in Asia that will bring together global partners and regional stakeholders to leverage partnership opportunities, learn about the latest technological advancements and spearhead scientific innovation. The event will play host to the Big Pharmas, International Biopharma, Asian Biopharma, Academic & Research Institutes, Regulatory Authorities, NGOs, Solution Providers, and Technocrats.
With this edition of Vaccine World Asia, we have co-located with Asia-Pacific Vaccine Excellence Awards. If Asia’s vaccine business matters to you, then Vaccine World Asia Congress 2021 is the place to be!
Conference Agenda
Vaccine World Asia Congress will be the only vaccine focused platform in Singapore for Asia that will bring together global partners and regional stakeholders to leverage partnership opportunities, learn about the latest technological advancements and spearhead scientific innovation. The event will play host to the BIG Pharmas, International Biopharma’s, Asian Biopharmas, Academic & Research Institutes, Regulatory Authorities, NGOs, Solution Providers and Technocrats. If Asia’s vaccines business matters to you, then Vaccine World Asia 2021 is the place to be!
Register Now!
2021 Speakers
Jerome H. Kim International Vaccine Institute
M.D, Director GeneralInternational Vaccine InstituteSouth Korea Jerome Kim, M.D., is an international expert on the evaluation and development of vaccines and is the Director-General of the International Vaccine Institute (IVI), whose mission is to discover, develop and deliver safe, effective, and affordable vaccines for Global Health. His depth and breadth of scientific experience span basic research through advanced clinical development. IVI’s oral cholera vaccine is used around the world to prevent this deadly diarrheal disease. IVI is working on several different vaccines against COVID-19, including the clinical testing of Inovio’s DNA vaccine at Seoul National University Hospital and Genexine’s COVID-19 vaccine at Severance Hospital.
Dr. Kim was Principal Deputy and Chief, Laboratory of Molecular Virology and Pathogenesis in the U.S. Military HIV Research Program (MHRP) and also served as the Project Manager for the HIV Vaccines and Advanced Concepts Evaluation Project Management Offices, U.S. Army Medical Materiel Development Activity, Fort Detrick, MD. He led the Army's Phase III HIV vaccine trial (RV144) which was the first demonstration that an HIV vaccine could protect against infection, as well as subsequent studies that identified laboratory correlates and HIV sequence changes associated with vaccination.
Dr. Kim has authored over 300 publications and received the John Maher Award for Research Excellence from the Uniformed Services University of the Health Sciences in 2013 and the Department of the Army R&D Award for Technical Excellence (2013). Dr. Kim is also an Adjunct Professor of Medicine at the Uniformed Services University of the Health Sciences and at Yonsei University Graduate School of Public Health and a Fellow of the American College of Physicians and the Infectious Diseases Society of America.
He is a graduate of the University of Hawaii, with high honors in History and highest honors in Biology, and received his M.D. from Yale University School of Medicine.
Zhong Kai Shi Yisheng Biopharma
Ph.D, Chief Medical OfficerYisheng BiopharmaChinaDr. Shi brings over 20 years of experience in global product development. Prior to joining Yisheng, Dr. Shi led global product development as Director of Clinical Development at the vaccine development organization Aeras. Before Aeras, Dr. Shi was Director of Vaccine Development at Altimmune. He received his M.D. from Beijing University and earned an MBA from the University of Alabama at Birmingham.
Han S Kierstead AIVITA Biomedical
CEOAIVITA BiomedicalUSA Dr. Keirstead is an internationally known stem cell expert and serial entrepreneur that has led therapy development for cancer, immune disorders, motor neuron diseases, spinal cord injury, and retinal diseases. He is the Chairman and CEO of AIVITA Biomedical. He has founded 4 successful biotechnology companies, each returning significant value to investors and treatments to patients. He holds Board positions in several prominent biotechnology companies. He was a full Professor at the University of California, Irvine where he founded, directed, and erected a building for the UCI Stem Cell Research Center. He was a founding advisor of the California Stem Cell Initiative that resulted in a $3 billion stem cell fund (CIRM). He has been a long-time advisor to several governments on biomedical policy. Dr. Keirstead received his Ph.D. in neuroscience from the University of British Columbia, Canada, receiving the Cameron Award for outstanding Ph.D. thesis in the country. He received the distinct honor of election as Senate Member of the University of Cambridge and Fellow of the Governing Body of Downing College and was the youngest member to have been elected to those positions.
Raches Ella Bharat Biotech
Project Lead: SARS-CoV-2 VaccineBharat BiotechIndia
Mark Newman GeoVax
Chief Scientific Officer, GeoVax, USA GeoVaxUSA Dr. Newman has more than 30 years of experience in the biotechnology sector serving in senior management roles at GeoVax (Atlanta, GA), PaxVax (San Diego, CA), Pharmexa (Horsholm, Denmark), Epimmune (San Diego, CA), Vaxcel (Atlanta, GA), Apollon (Philadelphia, PA) and Cambridge Biotech (Boston, MA) where he directed research, development and early-stage clinical testing of protein, peptide, plasmid DNA and viral vectored vaccines and multiple vaccine adjuvants. He participated with or directed teams responsible for the transition of 10 vaccine or vaccine-related products from the research stage to Phase 1 and 2 clinical testings. He also served as the primary scientific director for multiple corporate teams that completed Due Diligence reviews, technology assessments, and intellectual property reviews, and portfolio management to support strategic planning, technology in-licensing, and out-licensing, corporate partnering, and mergers and acquisitions.
Dr. Newman has co-authored more than 100 scientific papers, reviews, and book chapters during his professional career. He is a named co-inventor on multiple issued US and PCT patents, all related to vaccine technologies. He served as the Principal Investigator on multiple USA government and foundation grants and contracts and has served as a grant and contract review expert for 20 years for the National Institutes of Health.
Dr. Newman is a graduate of the Ohio State University (B.Sc. and M.Sc.) and received his Ph.D. in Immunology from the John Curtin School of Medical Research, the Australian National University (Canberra, Australia). He completed four years of post-doctoral training at Cornell University and the Uniformed Services University of Health Sciences under contract with the National Cancer Institute, National Institutes of Health. He also served four years as a full-time member of the Louisiana State University faculty at the School of Veterinary Medicine prior to joining the biotechnology industry in 1989.
Samir Desai Cadila Healthcare Limited (Zydus Cadila)
President & Head of BU Biologics Cadila Healthcare Limited (Zydus Cadila)India Industry experience of close to 3 decades having handled sales, training, brand management, marketing and commercial operations. Current role includes commercial operations for vaccines & biologics and small molecules across specialties & geographies, Business Development, In & Out licensing, portfolio planning. Extensively worked in the area of maternal health related public policy advocacy, improving access to HCV medicines etc. Handled vaccines since 2 decades.
Randall Hyer Moderna
MD, PhD, MPH, Senior Vice President, Global Medical Affairs, Moderna, USA ModernaUSA Dr. Hyer has over three decades of experience in medicine and public health in both the public and private sectors. After graduating with distinction from the US Naval Academy, he studied at Duke Medical School and then earned a Ph.D. in molecular biology from Oxford University. He then spent 13 months on the “ice” in Antarctica as the Station Physician for the winter. Dr. Hyer then shifted to public health and vaccines, serving four years at the World Health Organization as a medical officer responding to outbreaks and emergencies including anthrax, Ebola, SARS, avian influenza, as well as tsunamis and earthquakes. In response to the need for effective communication, Randy co-authored a popular WHO handbook on risk and crisis communication during public health emergencies. In industry, Randy’s experience covers vaccines, biologics, biosimilars, and small molecule development. He was pivotal to the 2017 approval of a two-dose adult hepatitis B vaccine (HEPLISAV-B), the first FDA-approved vaccine with a truly novel adjuvant. Beyond development, his responsibilities have included directing vaccine and pharmaceutical safety programs, overseeing vaccine clinical operations and biometrics functions, engaging medical scientists and policy-makers, and managing crises. Randy’s perspectives and contributions span his residing in eight and traveling to 100 plus countries in diverse roles across the public and private sectors.
Joseph Payne Arcturus Therapeutics
President & CEOArcturus TherapeuticsUSAJoseph E. Payne, is the President and Chief Executive Officer of Arcturus Therapeutics. He serves on Arcturus’s Board since March 2013. He brings with him an exceptional track record of ushering novel therapeutics to the clinic including targeted RNA medicines utilizing lipid-mediated delivery technologies. Joseph’s background includes over 20 years of successful drug discovery experience at Merck Research Labs, DuPont Pharmaceuticals, Bristol-Myers Squibb, Kalypsys, and Nitto as evidenced by over 40 publications and patents, and several investigational new drug (IND) clinical candidates. His academic training includes a Bachelor's Degree in Chemistry, magna cum laude from Brigham Young University, a Master of Science in Synthetic Organic Chemistry from the University of Calgary and Executive Training Certification from MIT Sloan School of Management.
Alexandre, Le Vert Osivax
CEOOsivaxFranceAlexandre has broad experience in healthcare ranging from research and development to commercialization of vaccines and therapeutics. He is an experienced entrepreneur in biotech and innovation. Alexandre is a Board Member of several biotech companies in France and in the US.
Ingrid Kromann CEPI
Head of CMCCEPIUK Ingrid Kromann started 01 March 2020 as Head of CMC, CEPI, UK. The CEPI CMC team is facilitating the vaccine developers in process development and scale-up activities.
Ingrid has a background as a chemical engineer. She has more than 25 years experience of working with vaccines through her employment at Statens Serum Institut, Denmark.
For the last 16 years, Ingrid led the Vaccine development department at Statens Serum Institut and has developed more than 10 different vaccines from research to clinical trials, mostly within Tuberculosis, Polio, and Chlamydia.
Rong Xu Clover Biopharmaceuticals
Senior Vice President, re-Clinical R&D (Vaccine)Clover BiopharmaceuticalsChina
Kevin Wang, Ph.D CC-Pharming Ltd.
Chairman/CSOCC-Pharming Ltd.China
Kiat Ruxrungtham, MD Department of Medicine Chulalongkorn University; and Scientific Chair of the Chula Vaccine Research Center (ChulaVRC)
Professor of MedicineDepartment of Medicine Chulalongkorn University; and Scientific Chair of the Chula Vaccine Research Center (ChulaVRC) Kiat Ruxrungtham, M.D, Scientific Mentor & Founder, Chula VRC & As Scientific Mentor & Founder of Chula VRC, Kiat Ruxrungtham conducts vaccine research work and gathering professors and researchers interested in the research and development of vaccines into Center of Excellence in Vaccine Research and Development. He spent more than 30 years exploring HIV treatment strategies, HIV T cell immunology, vaccine development (including dengue, HIV, and house dust mite (HDM) vaccine); and strategies to improve DNA vaccine immunogenicity. He has supervised and lead Chula VRC’s effect to rapidly advance the promising HDM vaccine candidates from the lab bench to clinical trial.
Ruxrungtham holds a Professor of Medicine from the Department of Medicine, Chulalongkorn University. He is providing teaching and patient care at the King Chulalongkorn Memorial Hospital and is mentoring junior researchers on the vaccine, immunology research, and also on clinical trials. He currently is a vice president for research and innovation, Chulalongkorn University.
He has published more than 230 peer review papers on HIV, immunology, and allergy. He is a faculty member of the faculty 1000 of Medicine, a chief editor of Asia Pacific J of Allergy, and an editorial board member of Immunology, ImmunoTargets and Therapy, Asian Biomedicine, and the Scientific Report. He is also a reviewer for > 9 journals.
Rajinder Kumar Suri DCVMN
CEODCVMNRajinder Kumar Suri joined DCVMN (Developing Countries Vaccine Manufacturers Network) as CEO w.e.f. Jan 15th, 2021. Before this, he was donning the hat of Chief Executive-Biologicals, Panacea Biotec Ltd. Rajinder has over 40 years of rich experience in Pharmaceuticals & Biological products in Indian & International markets out of which over 24 years’ experience at the top management level including four years on the Board of Directors of the Indian subsidiary of Sanofi Pasteur. The remaining 19 years were with Pharma out of which 16 years with Lupin. Mr. Suri brings with him over 3 years of consulting experience as CEO & Senior Advisor, Arete Business Advisors.
Rajinder has been Member-Policy & Planning Committee (PPC), an advisory body to GAVI Board, representing DCVMN from October 2013 till June 2017, as also a Member of the GAVI Steering Committee for Supply & Procurement Strategy. He has played a lead role in negotiations & interactions with the Ministry of Health, Government of India, UN agencies, and other Global organizations like WHO, UNICEF, Bill & Melinda Gates Foundation, Clinton Health Access Initiative & several others. Rajinder is also a former Member Executive Committee & Vice-President, DCVMN for a period of two years from Oct. 2014 - 2016.
Vasan K Sambandamurthy India Alliance
CEOIndia AllianceIndia Vasan Sambandamurthy joined the DBT/Wellcome Trust India Alliance in October 2020 with over 20 years of professional experience in vaccine discovery and drug development. He has previously worked for major global corporations like Novartis, AstraZeneca, and Biocon. At these organizations, Vasan has held senior leadership positions, provided strategic directions, and orchestrated major business operations to develop affordable medicines across multiple therapeutic areas including oncology, diabetes, infectious diseases (specifically in tuberculosis and malaria), and inflammation.
Vasan completed his post-doctoral training as a Howard Hughes Medical Institute (HHMI) fellow at the Albert Einstein College of Medicine in New York. He gained his Ph.D. from the Tuberculosis Research Centre (Indian Council of Medical Research) in Chennai and completed his post-graduate degree in Medical Microbiology from the Christian Medical College and Hospital in Vellore. He went on to leverage his academic training and real-world experience in managing large Research & Development portfolios, interdisciplinary and cross-functional global teams, regulatory submissions, and global alliances to advance diverse classes of molecules into clinical development.
In his spare time, Vasan is a prolific long-distance runner, avid trekker, and classical music enthusiast.
Dr. Farshad Guirakhoo COVAXX and VAXXINITY
Chief Scientific OfficerCOVAXX and VAXXINITYUSA
Elena Smith Sanofi Pasteur
Deputy Director, Analytical Expert - Quality (Protein Sciences Site)Sanofi PasteurUSA
Etleva Kadilli UNICEF
Director, Supply DivisionUNICEFCopenhagen, DenmarkEtleva (Eva) Kadilli is Director of UNICEF’s Supply Division, based in Copenhagen, Denmark, and oversees UNICEF's global supply chain functions with an annual expenditure exceeding USD 3.8 billion. In this capacity, she leads the effective, efficient, and ethical provision of essential and emergency supplies for children, through direct UNICEF programs, and in cooperation with national governments and partners.
Responsible for the management of UNICEF’s supply response to humanitarian crises, Ms. Kadilli is presently leading the organization’s strategic procurement and logistics emergency response to the COVID-19 pandemic. In this capacity, she represents UNICEF in the UN COVID Supply Chain Task Force and also represents the organization in a number of other global forums, including interagency engagements on UN procurement reform, and an alternate member of the Board of Gavi, the Vaccine Alliance. Ms. Kadilli also sits on Gavi’s Audit and Finance Committee, and Market Sensitive Decisions Committee.
A UNICEF staff member for nearly 25 years, Ms. Kadilli has held several roles at the headquarters and field levels, as well as in development and emergency contexts, including Albania, the Democratic Republic of the Congo (DRC), The Gambia, and Somalia. Ms. Kadilli has been with UNICEF’s Supply Division since 2011, where she previously held the position of Deputy Director, Supply Chain, overseeing teams responsible for contracting policy and procedures, quality assurance, global logistics operations, and emergency response. Her other roles have included Chief of Contracting, responsible for procurement oversight and compliance; and Contract Manager and Medical Unit Team Leader for health technology supplies in support of MNCH and HIV/AIDS programs, including during the 2014-2016 Ebola outbreak.
Yujiao Chen Beijing CC-Pharming
Co-Founder & Executive VPBeijing CC-PharmingChina
Dr. Gaurab Sircar Visva Bharati University, Santiniketan,
ProfessorVisva Bharati University, Santiniketan,IndiaCurrently working as a DBT/Wellcome Trust India Alliance Early Career Fellow at Visva-Bharati, Santiniketan. I obtained my MSc in Botany from Calcutta University followed by Ph.D. from Bose Institute, Kolkata. Following 3 years of postdoctoral training from Bose Institute and then from Harvard Medical School, Boston, MA, USA, I joined Visva-Bharati as an ECF. For the last 10 years, I have been pursuing research in the field of ‘Molecular Allergology and Clinical Immunology’ with an aim to develop molecular diagnostics and immunotherapeutics for allergic diseases. I am currently working on designing recombinant vaccines for patient-tailored immunotherapy to treat allergic asthma triggered by Aspergillus fumigatus, a ubiquitously present pathogenic mold.
Sanjeev Kumar, Ph.D International Centre for Genetic Engineering and Biotechnology (ICGEB),
DBT/Wellcome Trust India Alliance Early Career Fellow, ICGEB-Emory Vaccine ProgramInternational Centre for Genetic Engineering and Biotechnology (ICGEB), IndiaHe is presently working as a DBT-Wellcome Trust India Alliance Early Career Fellow at ICGEB-Emory Vaccine Program, ICGEB, Delhi, India. His present work involves studying the humoral antibody response against DENV and SARS-CoV-2 infections; isolation and characterization of human monoclonal neutralizing antibodies for viral infections and engineered viral antigen-based vaccine design using Reverse Vaccinology 2.0 approach. In the past as a part of his Ph.D. at AIIMS, New Delhi, India under the supervision of Prof. Kalpana Luthra, he worked on isolation and characterization of human anti-HIV-1 monoclonal antibodies using high-throughput antigen specific single B cell sorting technology. He has designed a protein based HIV-1C immunogen as a part of his EMBO short-term fellowship, Rogier Sanders Lab, AMC, Amsterdam. Further, he gained expertise in 10x genomics for single B cell-based Next-gen sequencing and BCR repertoire RNA-seq and data analysis from Dennis Burton Lab, The Scripps Research Institute, San Diego, CA, USA as a part of HIV Research Trust Scholarship, UK. In his master’s thesis work, he made human cross-neutralizing anti-HIV-1 scFvs against the CD4bs from a phage library constructed from HIV-1 clade-C infected Indian pediatric donors.
Ajoy Chakrabarti Bill & Melinda Gates Foundation
Portfolio And Platform LeadBill & Melinda Gates FoundationUSADr. Chakrabarti has over 25 years of diverse product development experience in both pharmaceutical and biotechnology companies. He joined the Gates Foundation in 2016, working across multiple polio vaccine programs to provide strategic guidance and product development expertise as part of the global effort to eradicate polio. Prior to joining the Foundation, he spent eight years leading cross-functional development teams working on anthrax therapeutics and vaccines, as well as nerve agent antidotes at Emergent BioSolutions
Matthew Downham CEPI
Sustainable Manufacturing LeadCEPIUnited KingdomDr. Downham studied a Bachelor of Sciences degree (with honors) in industrial biology at London South Bank Polytechnic (UK) which included a placement with Boehringer Mannheim (DE). He then completed a Ph.D. in biochemical engineering (Birmingham University, UK), a post-doctoral research fellowship - bio-molecular sciences (Liverpool John Moores University, UK), and a post-graduate certificate in further/higher education
(Bolton Institute, UK). He joined the biopharmaceutical industry in 1997 and has worked for Protherics (UK), Bavarian Nordic & Morphosys (DE), Novartis Vaccines & Diagnostics (IT) & AstraZeneca (UK).
Dr. Downham worked on the preclinical and early clinical development of a vaccine, antibody, or enzyme therapies for infectious, hypertension, inflammatory, and oncology indications. He was a European Registered Toxicologist (2010-18); Chair, Vaccines Europe Influenza working group (2017-20); Treasurer, International Federation of Pharmaceutical Manufacturers & Associations Influenza Vaccine Supply task force (2017-20); Vice-Chair, IFPMA Convention on Biological Diversity working group (2018-20).
Dr. Downham has also co-authored 29 publications/abstracts and 3 international patents and in January 2021, joined the Coalition for Epidemic Preparedness Innovations (UK) as the Sustainable Manufacturing Lead.
Key Relevant Information:
BSc Hons Industrial Biology (London South Bank Polytechnic, UK & Boehringer Mannheim, DE), Ph.D. Biochemical Engineering (Birmingham University, UK), PGCE (Bolton Institute, UK), post-doctoral research fellowship – biomolecular sciences (Liverpool John Moores University, UK) and an EU Registered Toxicologist (Royal Society of Biology UK, 2010-‘18) 25 years international biopharmaceutical industry: Boehringer Mannheim (DE), Protherics (UK), Bavarian Nordic & Morphosys (DE), Novartis Vaccines & Diagnostics (IT), AstraZeneca (UK).
Nguyen Tuyet Nga PATH
Vietnam Country Director, PATH, Vietnam PATHVietnam Dr. Nguyen Tuyet Nga is PATH’s country director for Vietnam. She leads a broad portfolio of projects that focus on vaccines and immunization; infectious diseases including HIV, tuberculosis, and malaria; non-communicable diseases including heart disease and diabetes; infection prevention and control and antimicrobial resistance; and health systems strengthening via digital tools, improved data and data use culture, and strengthened primary health care. Nga also leads on regional programs that provide support to health systems and providers in Cambodia, Laos, and other countries in the region.
Nga is a medical doctor with particular experience in epidemiology, infectious disease control, vaccine development, and immunization programs. She has more than 25 years of experience in vaccine development and production (including clinical trials and licensing), immunization programming, infectious disease control including for HIV and tuberculosis, and in leading teams that promote the use of digital solutions and data for more effective, efficient, and resilient health systems.
Nga has been working with PATH since 2009, working as a technical advisor and in program management roles across PATH’s vaccines and immunization, tuberculosis, and digital solutions and data portfolios. Nga became the Vietnam Program Team Leader in 2014, the Deputy Country Director in 2018, and the Vietnam Country Director in 2019.
Before joining PATH, Nga was the head of the Research and Development Department at VABIOTECH, one of the largest vaccine companies in Vietnam, and worked as a researcher in the National Institute of Hygiene and Epidemiology. She holds an MD from Hanoi Medical University, a Ph.D. in Epidemiology from the National Institute of Hygiene and Epidemiology, and completed post-doctoral training in emerging infectious diseases from the United States Center for Disease Control and Prevention in Atlanta.
Frank Malinoski Eveliqure Biotechnologies
CMOEveliqure BiotechnologiesAustria Dr. Malinouski has extensive, over twenty years of vaccine experience in preclinical, clinical, regulatory, medical affairs (post-licensure), safety, and business development, including board membership. He received a BA degree from Colby College in 1976 and trained in microbiology (Ph.D.; Rutgers University, 1981) and medicine (MD; Albany Medical College, 1985).
Throughout his career, he held numerous executive positions such as Director of Clinical Research at Lederle-Praxis Biologicals, Senior Vice President of Clinical and Medical Affairs at Nabi Biopharmaceuticals, Vice President of Medical Affairs at Wyeth, Chief Medical Officer, and Senior Vice President of Development for Oxxon Therapeutics, Inc, and Vice President and then Senior Vice President of Medical and Scientific Affairs at MedImmune, LLC. He served on the board of LigoCyte Pharmaceuticals, Inc., a biotech vaccine company in Bozeman, MT from March 2008 to March 2009 and is involved with the North Carolina Biotechnology Center in Wilmington, NC. Dr. Malinoski has authored or co-authored multiple scientific and vaccine-related publications and is a member of several editorial boards.
Daniel R. Vlock Alopexx
MD – Founder, CEOAlopexx
Dave E. Anderson VBI Vaccines
Chief Scientific OfficerVBI VaccinesUSAA dynamic and well-published immunologist with broad expertise in the areas of vaccine development, autoimmunity and tumor immunology, Dr. Anderson joined VBI full time in 2009 from Harvard Medical School, where he held a position as Assistant Professor. As a co-founder and Chief Scientific Officer of VBI, Dr. Anderson is an inventor of much of the Company’s intellectual property and actively manages its ongoing expansion. Dr. Anderson holds a Ph.D. from Harvard University and a B.S. from the University of California at Davis.
Ada Wong Sanofi
Asia Public Affairs LeadSanofiSingapore
Per Fischer Minervax
CEO,MinervaxDenmark Dr. Fischer is the CEO of MinervaX. has 25 years of experience in the biotech and pharmaceutical industry within product development and business development. He has founded and run several biotech companies, worked as a biotech consultant, and been an entrepreneur in residence with Novo Holdings. Primary therapeutic areas have been immunology, vaccines, hemostasis, and oncology. He holds a D.Phil. from the University of Oxford.
Kirill Dmitriev Russian Direct Investment Fund
Chief Executive OfficerRussian Direct Investment FundRussia Kirill Dmitriev heads the Russian Direct Investment Fund - one of the world's leading sovereign funds with a reserved capital of $10 billion under management. RDIF was established in 2011 on the initiative of the President and the Chairman of the Government of the Russian Federation. In all transactions, RDIF acts as a co-investor alongside major international investors, playing the role of a catalyst in attracting direct investment into Russia. RDIF has successfully invested with foreign partners in more than 90 projects totaling 2.1 trillion rubles and covering 95% of the regions of the Russian Federation. RDIF has established joint strategic partnerships with leading international co-investors from more than 15 countries totaling more than $40 billion.
Prior to becoming CEO of RDIF in 2011, Kirill Dmitriev headed a number of large private equity funds and completed a series of landmark transactions for Russia, including the sale of Delta Bank to General Electric, Delta Credit Bank to Société Générale, CTC Media to Fidelity Investments, among others. Mr. Dmitriev began his career at Goldman Sachs and McKinsey & Company.
He was appointed by the President of Russia as a member of the BRICS and APEC Business Councils. He serves as a member of the supervisory board of ALROSA, and of the boards of directors of Transneft, Rostelecom, Gazprombank, MDMG, Russian Railways , Rosseti and Skolkovo Foundation. Mr. Dmitriev is also on the boards of trustees of the Mariinsky Theatre, Lomonosov Moscow State University and National History Fund. He is Vice President of the Russian Union of Industrialists and Entrepreneurs.
S S Vasan CSIRO
Team LeaderCSIROAustralia
Luis Rios-Nogales ILiAD Biotechnologies
Chief Medical OfficerILiAD BiotechnologiesUSA
2021 Sponsors & Exhibitors
Platinum Sponsor
Silver Sponsor
Associate Sponsor
Technology Showcase Sponsor
Exhibitors
Advertiser
Supporter
Showcase Your Solutions To Asia's Top Vaccines Executives
Vaccine World Asia Congress 2021 will provide you with the opportunity to educate the market about your offerings and position yourselves as leaders in your field alongside key industry figures! This is an EXCEPTIONAL opportunity to position your brand and business before the Asia’s top vaccine executives. Make sure you get access to the region’s hottest life science sub-sector.
Market Intelligence
LATEST! eBook: Therapeutics & Prophylactic Vaccine Pipelines (Asia)
Exclusive! Challenges in Vaccine Development - A Regulatory Perspective
English 
简体中文 
日本語 
한국어 
繁體中文